SP
BravenNow
Simon, director, sells ImmunityBio (IBRX) shares worth $900k
| USA | economy | ✓ Verified - investing.com

Simon, director, sells ImmunityBio (IBRX) shares worth $900k

#ImmunityBio #Barry J. Simon #Insider Trading #ANKTIVA #Biotechnology #NASDAQ #Rule 10b5-1 #Clinical Trials

📌 Key Takeaways

  • ImmunityBio director Barry J. Simon sold 75,000 shares worth $900,787 on February 24, 2026
  • The sale was executed under a pre-arranged Rule 10b5-1 trading plan from September 2024
  • ImmunityBio reported strong financial performance with ANKTIVA revenue increasing 700% in 2025
  • The company has expanded globally through partnerships and shown positive clinical trial results

📖 Full Retelling

ImmunityBio director Barry J. Simon sold 75,000 shares of the biotechnology company on February 24, 2026, for a total transaction value of $900,787, according to recent regulatory filings. The shares were sold at a weighted average price of $12.0105, with individual transactions occurring between $12.00 and $12.025 per share. Following this transaction, Simon directly owns approximately 2.85 million shares of ImmunityBio, maintaining a significant stake in the company valued at $9.71 billion. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established on September 4, 2024, which is designed to prevent insider trading allegations by allowing executives to set up automated trading plans. ImmunityBio has shown strong financial performance recently, with its ANKTIVA product generating $113 million in revenue for 2025, representing a remarkable 700% increase compared to the previous year. The company has also experienced substantial growth in unit sales, reaching 3,745 units in 2025, a 750% increase from 2024. Additionally, ImmunityBio has made significant progress in its clinical trials, completing enrollment in a Phase 2 trial for ANKTIVA combined with Bacillus Calmette-Guérin for bladder cancer treatment, with interim results showing statistically significant improvements in response duration.

🏷️ Themes

Insider Trading, Biotechnology, Financial Performance, Market Expansion

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
Nasdaq

Nasdaq

American stock exchange

Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...

View Profile → Wikipedia ↗
Biotechnology

Biotechnology

Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain S&P 500, Nasdaq end in the red as Nvidia drags chip stocks lower Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Simon, director, sells ImmunityBio shares worth $900k By Investing.com Insider Trading Published 02/26/2026, 08:22 PM Simon, director, sells ImmunityBio shares worth $900k 0 IBRX 0.10% Director Barry J. Simon disposed of 75,000 shares of ImmunityBio, Inc. (NASDAQ:IBRX) on February 24, 2026. The shares were sold at a weighted average price of $12.0105, in a price range of $12.00 to $12.025, for a total transaction value of $900,787. The stock has since declined to $9.55, trading near its 52-week high of $12.43 but up significantly from its 52-week low of $1.83. Following the transaction, Simon directly owns 2,850,821 shares of ImmunityBio, Inc. The biotechnology company, valued at $9.71 billion, posted revenue of $113.29 million with an exceptional gross profit margin of 99.34%. According to InvestingPro Tips, while analysts anticipate sales growth this year, the company is not expected to be profitable in the near term. Investors can access 11 additional InvestingPro Tips for deeper insights into IBRX’s financial health and growth prospects. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. In other recent news, ImmunityBio reported significant financial results, with ANKTIVA generating $113 million in revenue for 2025, marking a 700% increase compared to 2024. The company also noted a substantial rise in unit sales, reaching 3,745 in 2025, which is a 750% increase from the previous year. Additionally, ImmunityBio completed enrollment in its Phase 2 clinical trial for ANKTIVA combined with Bacillus Calmette-Guérin in treating bladder cancer, with ...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine